P/E ratio for Bristol-Myers Squibb (BMY)
P/E ratio as of March 2023 (TTM): 21.4
According to Bristol-Myers Squibb's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 21.3921. At the end of 2021 the company had a P/E ratio of 19.7.
P/E ratio history for Bristol-Myers Squibb from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 19.7 | -226.77% |
| 2020 | -15.5 | -153.28% |
| 2019 | 29.1 | 69.66% |
| 2018 | 17.2 | |
| 2016 | 21.9 | -69.14% |
| 2015 | 70.9 | 45.37% |
| 2014 | 48.8 | 43.19% |
| 2013 | 34.1 | 21.27% |
| 2012 | 28.1 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 21.0 | -1.88% | 🇺🇸 USA |
 Novartis NVS | 8.46 | -60.44% | 🇨🇭 Switzerland |
 Pfizer PFE | 7.64 | -64.31% | 🇺🇸 USA |
 AbbVie ABBV | 23.2 | 8.44% | 🇺🇸 USA |
 Eli Lilly LLY | 49.7 | 132.35% | 🇺🇸 USA |
 Amgen AMGN | 18.5 | -13.49% | 🇺🇸 USA |
 Sanofi SNY | 14.5 | -32.23% | 🇫🇷 France |
 Biogen BIIB | 12.6 | -40.95% | 🇺🇸 USA |
 Merck MRK | 17.6 | -17.76% | 🇺🇸 USA |
 AstraZeneca AZN | 100 | 367.89% | 🇬🇧 UK |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.